Document is current
Any future updates will be listed below
-
Authors
Kurki, Samu N. http://orcid.org/0000-0002-7531-0957
Kantonen, Jonas
Kaivola, Karri
Hokkanen, Laura
Mäyränpää, Mikko I.
Puttonen, Henri
,
Martola, Juha
Pöyhönen, Minna
Kero, Mia
Tuimala, Jarno
Carpén, Olli
Kantele, Anu
Vapalahti, Olli
Tiainen, Marjaana
Tienari, Pentti J.
Kaila, Kai
Hästbacka, Johanna
Myllykangas, Liisa http://orcid.org/0000-0002-2237-5466
-
Funding
Funding for this research was provided by:
Terveyden Tutkimuksen Toimikunta (341007, 336439, 335527)
Juho Vainion Säätiö
Suomen Lääketieteen Säätiö
Helsingin ja Uudenmaan Sairaanhoitopiiri (TYH2021310)
Helsingin Yliopisto
nordforsk
Sigrid Juséliuksen Säätiö
Suomen Aivosäätiö
- License Information
-
More Information
Article History
Received: 27 October 2021
Accepted: 2 December 2021
First Online: 23 December 2021
Declarations
:
: Patients and controls in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act (). All DNA samples and data were pseudonymised. Participants of the RECOVID-study [protocol approved by Ethical board of Helsinki University Hospital (HUS/1949/2020)] provided written informed consent. Clinical autopsies were performed at the Department of Pathology, HUS Diagnostic Center, Helsinki University Hospital according to Finnish legislation, with consent granted by the next of kin. The protocol covering COVID-19 autopsies was approved by the Ethics Committee of Helsinki University Hospital (HUS/1238/2020).
: A consent to publish individual pictures/details was obtained from the subjects or their next-of-kin.
: Pentti J. Tienari holds a patent on C9orf72 in diagnostics and treatment of ALS/FTD and has made paid consultations to Roche, Biogen, Merck, Teva, Sanofi-Genzyme and Novartis. Other authors declare no conflicts of interest.
